[1]杨敏 殷跃辉 陈芸霖 杨仙 易鑫 崔犇.心力衰竭临床预后预测模型研究进展[J].心血管病学进展,2023,(10):878.[doi:10.16806/j.cnki.issn.1004-3934.2023.10.004]
　YANG Min,YIN Yuehui,CHEN Yunlin,et al.Research Status of Clinical Prediction Model for Heart Failure Prognosis[J].Advances in Cardiovascular Diseases,2023,(10):878.[doi:10.16806/j.cnki.issn.1004-3934.2023.10.004]
点击复制

心力衰竭临床预后预测模型研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2023年10期
页码:
878
栏目:
综述
出版日期:
2023-10-25

文章信息/Info

Title:
Research Status of Clinical Prediction Model for Heart Failure Prognosis
作者:
杨敏1 殷跃辉; 2 陈芸霖2 杨仙1 易鑫1 崔犇1
(1.重庆医科大学研究生院,重庆 400010;2.重庆医科大学附属第二医院心血管内科,重庆 400010)
Author(s):
YANG Min1; YIN Yuehui1; 2; CHEN Yunlin2; YANG Xian1; YI Xin1; CUI Ben1
(1.Chongqing Medical University Graduate School,Chongqing 400010,China2.Department of Cardiology,The Second Affiliated Hospital of Chongqing Medical University,Chongqing 400010,China)
关键词:
心力衰竭; 预测模型; 风险评分
Keywords:
Heart failure;  Prognostic models;  Risk score
DOI:
10.16806/j.cnki.issn.1004-3934.2023.10.004
摘要:
心力衰竭（HF)是多种心血管疾病发展的终末期阶段。随着社会老年化的加重，其发病率、再住院率和死亡率逐年增加。根据HF的类型和病情不同，患者的病死率可能存在明显差异。目前许多国家和地区已经建立了多种用于预测HF患者死亡风险的客观评估模型，在为不同危险分层的患者拟定医疗管理策略和治疗方案时提供了重要的决策辅助支持。不同的临床预测模型各有其临床使用特点，适用于不同HF类型的临床患者。现旨在从不同HF类型患者人群入手，对国际上预测HF患者发生不良预后的预警模型研究现状进行概述。
Abstract:
Heart failure（HF) is a serious condition of various heart diseases in the late stage. With the aggravation of social aging ,its morbidity,readmission rate and mortality increase year by year. Depending on the type and condition of HF,the mortality of patients may be significantly different. At present,many countries and regions have established a great variety of objective assessment models for predicting the risk of death in HF patients ,which provides important decision aid support in the formulation of medical management strategies and treatment plans for patients with different risk stratification. Different clinical prediction models have their own clinical application characteristics and are suitable for different types of HF patients. In this paper ,we will introduce various common HF prognostic models from different types of patients with HF

参考文献/References:

[1]. 中国心血管健康与疾病报告编写组.中国心血管健康与疾病报告2021概要[J].中国循环杂志,2022,37(06):553-578.
[2]. Aaronson KD,Schwartz JS,Chen TM,et al. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation[J]. Circulation,1997,95(12):2660-2667.
[3]. Levy WC,Mozaffarian D,Linker DT,et al. The Seattle Heart Failure Model:prediction of survival in heart failure[J]. Circulation,2006,113(11):1424-1433.
[4]. Simpson J,Jhund PS,Lund LH,et al. Prognostic models derived in PARADIGM-HF and validated in ATMOSPHERE and the Swedish Heart Failure Registry to predict mortality and morbidity in chronic heart failure[J]. JAMA Cardiol,2020,5(4):432-441.
[5]. O’Connor CM,Whellan DJ,Wojdyla D,et al. Factors related to morbidity and mortality in patients with chronic heart failure with systolic dysfunction:the HF-ACTION predictive risk score model[J]. Circ Heart Fail,2012,5(1):63-71.
[6]. Bilchick KC,Stukenborg GJ,Kamath S,et al. Prediction of mortality in clinical practice for medicare patients undergoing defibrillator implantation for primary prevention of sudden cardiac death[J]. J Am Coll Cardiol,2012,60(17):1647-1655.
[7]. Komajda M,Carson PE,Hetzel S,et al. Factors associated with outcome in heart failure with preserved ejection fraction:findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE) [J]. Circ Heart Fail,2011,4(1):27-35.
[8]. Thorvaldsen T,Claggett BL,Shah A,et al. Predicting risk in patients hospitalized for acute decompensated heart failure and preserved ejection fraction:the Atherosclerosis Risk in Communities Study Heart Failure Community Surveillance[J]. Circ Heart Fail,2017,10(12):e003992.
[9]. Stempfle HU,Alt A,Stief J,Siebert U. The Munich score:a clinical index to predict survival in ambulatory patients with chronic heart failure in the era of new medical therapies[J]. J Heart Lung Transplant,2008,27(2):222-228.
[10]. Pocock SJ,Ariti CA,McMurray JJ,et al. Predicting survival in heart failure:a risk score based on 39 372 patients from 30 studies[J]. Eur Heart J,2013,34(19):1404-1413.
[11]. Pocock SJ,Wang D,Pfeffer MA,et al. Predictors of mortality and morbidity in patients with chronic heart failure[J]. Eur Heart J,2006,27(1):65-75.
[12]. Bozkurt B,Coats A,Tsutsui H. Universal definition and classification of heart failure[J]. J Card Fail,2021,S1071-9164(21)00050-6.
[13]. Parikh MN,Lund LH,Goda A,et al. Usefulness of peak exercise oxygen consumption and the heart failure survival score to predict survival in patients >65 years of age with heart failure[J]. Am J Cardiol,2009,103(7):998-1002.
[14]. Franke J,Lindmark A,Hochadel M,et al. Gender aspects in clinical presentation and prognostication of chronic heart failure according to NT-proBNP and the Heart Failure Survival Score[J]. Clin Res Cardiol,2015,104(4):334-341.
[15]. Goda A,Lund LH,Mancini DM. Comparison across races of peak oxygen consumption and heart failure survival score for selection for cardiac transplantation[J]. Am J Cardiol,2010,105(10):1439-1444.
[16]. Goda A,Lund LH,Mancini D. The Heart Failure Survival Score outperforms the peak oxygen consumption for heart transplantation selection in the era of device therapy[J]. J Heart Lung Transplant,2011,30(3):315-325.
[17]. Regoli F,Scopigni F,Leyva F,et al. Validation of Seattle Heart Failure Model for mortality risk prediction in patients treated with cardiac resynchronization therapy[J]. Eur J Heart Fail,2013,15(2):211-220.
[18]. Bilchick KC,Wang Y,Cheng A,et al. Seattle Heart Failure and Proportional Risk?Models predict benefit from implantable?cardioverter-defibrillators[J]. J Am Coll Cardiol,2017,69(21):2606-2618.
[19]. Smith T,Levy WC,Schaer BA,et al. Performance of the Seattle Heart Failure Model in implantable defibrillator patients treated with cardiac resynchronization therapy[J]. Am J Cardiol,2012,110(3):398-402.
[20]. Bilchick KC,Auger DA,Abdishektaei M,et al. CMR DENSE and the Seattle?Heart?Failure?Model inform survival and arrhythmia risk after CRT[J]. JACC Cardiovasc Imaging,2020,13(4):924-936.
[21]. Kalogeropoulos AP,Georgiopoulou VV,Giamouzis G,et al. Utility of the Seattle Heart Failure Model in patients with advanced heart failure[J]. J Am Coll Cardiol,2009,53(4):334-342.
[22]. Li S,Marcus P,Nú?ez J,et al. Validity of the Seattle Heart Failure Model after heart failure hospitalization[J]. ESC Heart Fail,2019,6(3):509-515.
[23]. Sartipy U,Dahlstr?m U,Edner M,et al. Predicting survival in heart failure:validation of the MAGGIC heart failure risk score in 51,043 patients from the Swedish heart failure registry[J]. Eur J Heart Fail,2014,16(2):173-179.
[24]. Januzzi JL Jr,Zannad F,Anker SD,et al. Prognostic importance of NT-proBNP and?effect of empagliflozin in the EMPEROR-Reduced trial[J]. J Am Coll Cardiol,2021,78(13):1321-1332.
[25]. Packer M,Januzzi JL,Ferreira JP,et al. Concentration-dependent clinical and prognostic importance of high-sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin:the EMPEROR-Reduced trial[J]. Eur J Heart Fail,2021,23(9):1529-1538.
[26]. Ferreira JP,Anker SD,Butler J,et al. Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction:findings from EMPEROR-Reduced[J].Eur J Heart Fail,2022,24(4):708-715.
[27]. Beldhuis IE,Myhre PL,Claggett B,et al. Efficacy and safety of spironolactone in patients with HFpEF and chronic kidney?disease[J]. JACC Heart Fail,2019,7(1):25-32.
[28]. Alba AC,Agoritsas T,Jankowski M,et al. Risk prediction models for mortality in ambulatory patients with heart failure:a systematic review[J]. Circ Heart Fail,2013,6(5):881-889.

相似文献/References:

[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
　DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(10):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
　LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(10):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
　ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(10):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
　LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(10):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
　KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(10):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
　SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(10):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[7]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
　XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(10):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[8]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
　GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(10):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[9]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
　HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(10):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[10]吴彤 高东来.心房颤动合并心力衰竭的射频消融治疗[J].心血管病学进展,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
　WU TongGAO Donglai.Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2019,(10):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]

更新日期/Last Update: 2023-11-15